SCHEMBL748643

SCHEMBL748643

COc1ccc(-c2oc3cc(OC)cc(O)c3c(=O)c2O)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.90
CYP1A1 P04798 4/20 0.88
CYP1A2 P05177 4/20 0.88
CYP1B1 Q16678 4/20 0.88
ABCB1 P08183 4/20 0.88
FTO Q9C0B1 2/20 0.88
CYP3A4 P08684 5/20 0.81
MAPT P10636 5/20 0.81
KDM4E B2RXH2 4/20 0.81
MEN1 O00255 4/20 0.81
KMT2A Q03164 4/20 0.81
HSD17B10 Q99714 3/20 0.81
LMNA P02545 3/20 0.81
IPMK Q8NFU5 3/20 0.81
IP6K2 Q9UHH9 3/20 0.81
APP P05067 2/20 0.81
AKR1B1 P15121 2/20 0.81
TDP1 Q9NUW8 2/20 0.81
THRB P10828 1/20 0.81
RECQL P46063 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rhamnocitrin SCHEMBL29903288 0.95 MAOA (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Rhamnocitrin SCHEMBL1759429 0.95 MAOA (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Kaempferide SCHEMBL29371282 0.93 CYP1A2 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Kaempferide SCHEMBL426774 0.93 CYP1A2 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Izalpinin SCHEMBL29974286 0.91 MAOA (0.83) MAOACYP1A1CYP1A2CYP1B1ABCB1
Izalpinin SCHEMBL7551775 0.91 MAOA (0.83) MAOACYP1A1CYP1A2CYP1B1ABCB1
Rhamnetin SCHEMBL29496169 0.90 MEN1 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Rhamnetin SCHEMBL555118 0.90 MEN1 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Rhamnetin SCHEMBL29453025 0.90 MEN1 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1
Rhamnetin SCHEMBL7164573 0.90 MEN1 (1.00) MAOACYP1A1CYP1A2CYP1B1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111233807-A Preparation method and quality control method of high-purity kaempferol-7, 4' -dimethyl ether 广西壮族自治区中医药研究院 2020-06-05 CN claimed
US-20240115645-A1 DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR HONG ZHANG (CN) 2024-04-11 US disclosed
CN-117723684-A Cordate houttuynia quality analysis method based on metabonomics 中山市中智药业集团有限公司 2024-03-19 CN disclosed
CN-111233807-B Preparation method and quality control method of high-purity kaempferol-7, 4' -dimethyl ether 广西壮族自治区中医药研究院 2023-08-11 CN disclosed
WO-2022151978-A1 DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR 张弘 2022-07-21 WO disclosed
CN-108882744-B Composition containing fructus alpiniae oxyphyllae extract and application of fructus alpiniae oxyphyllae extract 韩国韩医学研究院 2022-04-19 CN disclosed
US-20200268827-A1 COMPOSITION FOR PREVENTION, IMPROVEMENT OR TREATMENT OF OSTEOARTHRITIS COMPRISING ALPINIA OXYPHYLLA EXTRACT AS EFFECTIVE COMPONENT KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) 2020-08-27 US disclosed
US-10709754-B2 Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of Alpinia oxyphylla as effective ingredient KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) 2020-07-14 US disclosed
CN-111233807-A Preparation method and quality control method of high-purity kaempferol-7, 4' -dimethyl ether 广西壮族自治区中医药研究院 2020-06-05 CN disclosed
US-20190099465-A1 COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING HYPERURICEMIA OR METABOLIC DISORDERS RELATED WITH HYPERURICEMIA COMPRISING EXTRACT OF ALPINIA OXYPHYLLA AS EFFECTIVE INGREDIENT KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) 2019-04-04 US disclosed
US-20110065786-A1 SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES TRUSTEES OF BOSTON UNIVERSITY 2011-03-17 US disclosed
US-7816544-B2 Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species TRUSTEES OF BOSTON UNIVERSITY (US) 2010-10-19 US disclosed
US-7816544-B2 Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species TRUSTEES OF BOSTON UNIVERSITY (US) 2010-10-19 US disclosed
US-20090299081-A1 Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids TRUSTEES OF BOSTON UNIVERSITY (US) 2009-12-03 US disclosed
US-20090299081-A1 Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids TRUSTEES OF BOSTON UNIVERSITY (US) 2009-12-03 US disclosed
US-20080177093-A1 Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species TRUSTEES OF BOSTON UNIVERSITY 2008-07-24 US disclosed
US-20080177093-A1 Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species TRUSTEES OF BOSTON UNIVERSITY 2008-07-24 US disclosed
WO-2007139749-A2 ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS TRUSTEES OF BOSTON UNIVERSITY (US) 2007-12-06 WO disclosed
US-5492911-A Linsidomine for the treatment for erectile dysfunctions Stief, Christian (DE) 1996-02-20 US disclosed
WO-1990006104-A1 USE OF KAEMPFEROL AND CERTAIN DERIVATIVES THEREOF FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION LVMH RECHERCHE (FR) 1990-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299081-A1 Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids NFKBIA, NFKB1, NFE2L2 MAOA 1855/4885CYP1A1 558/4885CYP1A2 617/4885
US-20240115645-A1 DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR HK1, HKDC1, HK2 MAOA 2130/4885CYP1A1 3173/4885CYP1A2 3504/4885
US-20110065786-A1 SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES NFKBIA, NFE2L2, NFKB1 MAOA 1402/4885CYP1A1 262/4885CYP1A2 215/4885
US-20080177093-A1 Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species NFKBIA, NFE2L2, NFKB1 MAOA 1402/4885CYP1A1 262/4885CYP1A2 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.